menu
    • menu
    [{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2020","type":"Series B Financing","leadProduct":"INV-101","moa":"CB1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inversago Pharma","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Inversago Pharma \/ Forbion","highestDevelopmentStatusID":"6","companyTruncated":"Inversago Pharma \/ Forbion"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"INV-101","moa":"CB1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inversago Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Inversago Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inversago Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"INV-101","moa":"CB1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inversago Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inversago Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inversago Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"INV-202","moa":"CB1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inversago Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Inversago Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inversago Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"INV-202","moa":"CB1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inversago Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Inversago Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inversago Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"INV-202","moa":"Peripheral CB1 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Inversago Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet\n","sponsorNew":"Inversago Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inversago Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"INV-202","moa":"Peripheral CB1 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Inversago Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inversago Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inversago Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"INV-202","moa":"Peripheral CB1 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Inversago Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inversago Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inversago Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"New Enterprise Associates","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Series C Financing","leadProduct":"INV-202","moa":"Peripheral CB1 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Inversago Pharma","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0.10000000000000001,"dosageForm":"Tablet","sponsorNew":"Inversago Pharma \/ New Enterprise Associates","highestDevelopmentStatusID":"8","companyTruncated":"Inversago Pharma \/ New Enterprise Associates"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"INV-202","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Inversago Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inversago Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inversago Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"INV-202","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Inversago Pharma","amount2":1.0800000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":1.0800000000000001,"dosageForm":"","sponsorNew":"Inversago Pharma \/ Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"Inversago Pharma \/ Novo Nordisk"}]

    Find Clinical Drug Pipeline Developments & Deals by Inversago Pharma

    Menu

    Inversago Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Inversago Pharma

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Inversago Pharma

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INV-202

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Novo Nordisk

                            Deal Size : $1,075.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Novo Nordisk to Acquire Inversago Pharma to Develop New Therapies for People Living with Obesity, Diabetes and...

                            Details : Through the acquisition, Inversago will further strengthen Nordisk's clinical pipeline in obesity, diabetes and other metabolic diseases by including its lead development asset INV-202, an oral CB1 inverse agonist, currently in a phase 2 trial for diabet...

                            Brand Name : INV-202

                            Molecule Type : Small molecule

                            Upfront Cash : $1,075.0 million

                            August 10, 2023

                            Lead Product(s) : INV-202

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Novo Nordisk

                            Deal Size : $1,075.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Inversago Pharma

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Inversago Pharma

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INV-202

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Inversago Pharma Doses First Patient in Phase 2 Trial of INV-202, an Oral, Peripherally-acting CB1 Inverse Ago...

                            Details : INV-202 is a small molecule CB1 inverse agonist being developed by Inversago for the potential treatment of a range of cardiometabolic and fibrotic conditions, including diabetic kidney disease.

                            Brand Name : INV-202

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 29, 2022

                            Lead Product(s) : INV-202

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Inversago Pharma

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Inversago Pharma

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INV-202

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : New Enterprise Associates

                            Deal Size : $95.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Inversago Pharma Raises $95 million CAD in Series C Financing

                            Details : Proceeds from financing will be used to move lead program, INV-202, into a Phase 2 in Diabetic Kidney Disease in Q4 2022. Additionally, the funds will accelerate other programs currently in pre-clinical development, while establishing its leadership in C...

                            Brand Name : INV-202

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 17, 2022

                            Lead Product(s) : INV-202

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : New Enterprise Associates

                            Deal Size : $95.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Inversago Pharma

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Inversago Pharma

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INV-202

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Inversago Pharma Receives IND Clearance for Phase 2 Trial of INV-202 in Diabetic Kidney Disease

                            Details : INV-202 showed a favorable profile in a first-in-human study, including safety and tolerability, oral absorption, and pharmacokinetics. It also demonstrated potential for decreased appetite, a relevant pharmacodynamic marker of early efficacy of Inversag...

                            Brand Name : INV-202

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 15, 2022

                            Lead Product(s) : INV-202

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Inversago Pharma

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Inversago Pharma

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INV-202

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Inversago Pharma Presents Data on INV-202 in Diabetic Nephropathy at the ERA 2022 Congress

                            Details : INV-202 is a small molecule CB1 inverse agonist / antagonist being developed by Inversago for the potential treatment of several metabolic conditions, including Diabetic Nephropathy.

                            Brand Name : INV-202

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 19, 2022

                            Lead Product(s) : INV-202

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Inversago Pharma

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Inversago Pharma

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INV-202

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Inversago Pharma Announces Dosing of First Participant With Metabolic Syndrome in Phase 1B Clinical Trial

                            Details : INV-202, first-in-class, peripheral CB1 inhibitor, demonstrated efficacy in addressing multiple pathways involved in renal injury also have shown clinical improvements in lipids, weight loss and glucose.

                            Brand Name : INV-202

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 15, 2022

                            Lead Product(s) : INV-202

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Inversago Pharma

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Inversago Pharma

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INV-202

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Inversago Pharma Initiates a Phase 1 Clinical Trial on INV-202, a Next Generation Peripherally-acting CB1 Bloc...

                            Details : As a next generation peripheral CB1 inverse agonist / antagonist, INV-202 has the potential to treat various metabolic conditions such as Prader-Willi Syndrome, non-alcoholic steatohepatitis, type 1 diabetes, diabetic nephropathy and chronic kidney disea...

                            Brand Name : INV-202

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 07, 2021

                            Lead Product(s) : INV-202

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Inversago Pharma

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Inversago Pharma

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INV-202

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Inversago Pharma Begins a Phase 1 Clinical Trial with INV-202, A New Generation Peripheral Action CB1 Blocker

                            Details : As a new generation peripheral CB1 inverse agonist / antagonist, INV-202 has the potential to treat various metabolic conditions such as Prader-Willi syndrome (PWS), NASH, type 1 diabetes (T1D), diabetic nephropathy and chronic kidney diseases, among oth...

                            Brand Name : INV-202

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 07, 2021

                            Lead Product(s) : INV-202

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Inversago Pharma

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Inversago Pharma

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INV-101

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Inversago Pharma Receives Rare Pediatric Disease Designation from the FDA for INV-101 for the Treatment of Pra...

                            Details : INV-101 is a first-in-class, small molecule CB1 inverse agonist / antagonist being developed by Inversago for the treatment of PWS and non-alcoholic steatohepatitis (NASH).

                            Brand Name : INV-101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 07, 2021

                            Lead Product(s) : INV-101

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Inversago Pharma

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Inversago Pharma

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INV-101

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Inversago Pharma Initiates Clinical Trials, with a Phase 1 study of INV-101, the Company’s Lead Peripheral C...

                            Details : The trial will evaluate the safety, tolerability and pharmacokinetics of INV-101. Inversago will enroll healthy participants in Canada, from 18 to 55 years old. Subjects will initially be randomized to receive a single dose of placebo or one of 5 dose le...

                            Brand Name : INV-101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 29, 2020

                            Lead Product(s) : INV-101

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth